A dispute between Médecins Sans Frontières (MSF) and Gilead Sciences has entered the public domain after the pharma company refused to sell its game-changing HIV-prevention medicine despite multiple requests. Lenacapavir, a twice-yearly injectable form of PrEP, could be a game changer, especially for people who struggle to access daily medication.
In an open letter Chief Executive Officer, MSF USA, Tirana Hassan and Director, Southern Africa Medical Unit, MSF Southern Africa, Dr Tom Ellman, call on Gilead to review their decision.
“That this drug’s development was supported by public funding – and through the trust of communities who participated in clinical trials, many of them in countries now excluded from affordable access – makes the current restrictions even more unconscionable,” write the MSF officials…
